The Impact of Deferasirox on Non-Alcoholic-Steatohepatitis (DEFINE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01278056
Recruitment Status : Completed
First Posted : January 17, 2011
Last Update Posted : July 20, 2012
Estimate, GmbH
University of Magdeburg
Information provided by (Responsible Party):
Crolll Gmbh

January 14, 2011
January 17, 2011
July 20, 2012
March 2010
March 2012   (Final data collection date for primary outcome measure)
  • Safety and tolerability of deferasirox in all patients (Phase I) [ Time Frame: Phase I: 12 weeks of treatment ]
    Safety and tolerability assessments will consist of evaluating (serious) adverse events, laboratory parameters including hematology, chemistry; vital signs and physical examinations according to CTC.
  • Changes in liver histology in all patients (Phase II) [ Time Frame: Phase II: 48 weeks of treatment ]
    A decrease in the NASH activity score (NAS) of ≥1 compared to baseline will be classified as response, an unchanged score or an increase in NAS will be judged as non-response.
Safety and tolerability of deferasirox (Phase I); Changes in liver histology (Phase II) [ Time Frame: Phase I: 12 weeks, Phase II: 48 weeks of treatment ]
Complete list of historical versions of study NCT01278056 on Archive Site
  • Phase I: e.g. changes in liver enzymes, serum ferritin, and hemoglobin levels [ Time Frame: Phase I: 12 weeks of treatment ]
  • Phase II: e.g. changes in MRI and histology based assessment of hepatic steatosis, fibrosis and iron content [ Time Frame: Phase II: 48 weeks of treatment ]
Not Provided
Not Provided
Not Provided
The Impact of Deferasirox on Non-Alcoholic-Steatohepatitis
The Impact of Deferasirox on Non-Alcoholic-Steatohepatitis (NASH) - a Prospective Open Label Phase I/II Trial

This is a Phase I/II open-label uncontrolled, prospective study to assess the clinical and biological effects of Deferasirox (ICL 670, Exjade®) in patients with NASH and increased iron storage / distribution of iron on liver function and liver histology.

NASH is defined clinically and histologically by elevated liver enzymes, signs of hepatic steatosis on ultrasound and magnetic resonance imaging, impaired liver function as expressed by functional breath tests, and significantly altered liver histology.

Patients will be treated in a phase I and phase II part for either 12 or 48 weeks.

Both study parts have different endpoints: in phase I the side effect profile will be evaluated while in phase II the therapeutic response will be tested. Accordingly, measures will be different.

Approximately 10 patients in phase I and 50 patients in phase II will be enrolled according to sample size calculations.

The design is an "adaptive" Two-stage design, allowing to minimize the number of patients included into the trial as well as to introduce corrections for the second stage.

Not Provided
Phase 1
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Non-alcoholic Steatohepatitis
  • Increased Iron Storage / Disturbed Distribution
Drug: Exjade
Two dose escalating cohorts of oral administration in Phase I. Phase II: oral administration of the maximum tolerated dose.
Other Name: Deferasirox, ICL670
Experimental: Exjade
Intervention: Drug: Exjade
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
July 2012
March 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria (shortened):

  • Patients with elevated liver enzymes
  • Elevated serum ferritin (females > 300 ng/ml, males > 450 ng/ml)
  • Liver Histology consistent with a diagnosis of NASH

Exclusion Criteria (shortened):

  • Alcohol intake > 140 g/week
  • Established liver cirrhosis Child Pugh B or C
  • Copresence of other causes of chronic liver disease
  • Anemia < 10 g/dl
  • Any elevation of liver enzymes > 5 ULN (ALAT, ASAT, g-GT), > 2.5 ULN (other), > 1.5 (Bilirubin)
  • Serum creatinine > 1.4 mg/dl or Ccr < 60 ml/min
  • Hemochromatosis
  • Known allergy or contraindication to the administration of Deferasirox
  • Sexually active pre-menopausal female patients who are unable to use a highly effective method of birth control. An exception is made for those who have undergone clinically documented total hysterectomy and/or oophorectomy, tubal ligation.
  • Patients with impaired coagulation
  • History of blood transfusion during the 6 months prior to study entry
  • Oral iron supplementation within the last 4 weeks of study entry
  • Treatment with phlebotomy within 2 weeks of screening visit
  • Desferal treatment within 1 month of the screening visit
  • Patients currently or previously treated with deferiprone or Deferasirox
  • Presence of a surgical or medical condition that might significantly alter the absorption, distribution, metabolism or excretion of any study drug
  • Positive HIV serology
  • Patients with active inflammatory diseases that may interfere with the accurate measurement of serum ferritin
  • Patients with a diagnosis of a clinically relevant cataract or a previous history of clinically relevant ocular toxicity related to iron chelation
  • Pregnant or breast feeding patients
  • Patients treated with systemic investigational drug within 4 weeks prior or with topical investigational drug within 7 days prior to the screening visit
  • Medications with proven or suspected influence on NASH such as glitazones, statins, or metformin are no exclusion criteria for study entry (insulin is not regarded to interfere with NASH).
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Crolll Gmbh
Crolll Gmbh
  • Estimate, GmbH
  • University of Magdeburg
Principal Investigator: Gerhard Treiber, PD Dr. med.
Crolll Gmbh
July 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP